Evidence map›Paper›PMID 32583332›Full record

ArticlePathology oncology research : POR2020

Elevated Microparticles, Thrombin-antithrombin and VEGF Levels in Colorectal Cancer Patients Undergoing Chemotherapy.

Marek Z Wojtukiewicz, Marta Mysliwiec, Ewa Sierko, Monika Sobierska, Joanna Kruszewska, Alina Lipska, Piotr Radziwon, Stephanie C Tucker, Kenneth V Honn

Open access · hybridAbstract read
In one paragraph

Article in Pathology oncology research : POR, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.7field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Platelet-Derived Procoagulant Microparticles as Blood-based Biomarker of Breast Cancer.Asian Pacific journal of cancer prevention : APJCP · 2021
    Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Marek Z WojtukiewiczDepartment of Oncology, Medical University of Bialystok, 12 Ogrodowa St, 15-027, Bialystok, Poland. mzwojtukiewicz@gmail.com.ORCID http://orcid.org/0000-0002-7604-8188
Marta MysliwiecDepartment of Oncology, Medical University of Bialystok, 12 Ogrodowa St, 15-027, Bialystok, Poland.
Ewa SierkoDepartment of Oncology, Medical University of Bialystok, 12 Ogrodowa St, 15-027, Bialystok, Poland.
Monika SobierskaDepartment of Oncology, Medical University of Bialystok, 12 Ogrodowa St, 15-027, Bialystok, Poland.
Joanna KruszewskaDepartment of Oncology, Medical University of Bialystok, 12 Ogrodowa St, 15-027, Bialystok, Poland.
Alina LipskaRegional Centre for Transfusion Medicine, Bialystok, Poland.
Piotr RadziwonRegional Centre for Transfusion Medicine, Bialystok, Poland.
Stephanie C TuckerBioactive Lipids Research Program, Department of Pathology-School of Medicine, Wayne State University, Detroit, MI, 48202, USA.
Kenneth V HonnBioactive Lipids Research Program, Department of Pathology-School of Medicine, Wayne State University, Detroit, MI, 48202, USA.
Medical University of Białystok · PLWayne State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hypercoagulable state and neoangiogenesis are common phenomena associated with malignancy. Cancer patients have increased levels of circulating endothelium-derived microparticles (EMPs), which have been hypothesized to be involved in numerous pathophysiological processes. Hemostasis and angiogenesis are also activated in colorectal cancer (CRC) patients. The study aimed to investigate potential influence of chemotherapy on EMPs, thrombin anti-thrombin complex (TAT) and vascular endothelial growth factor (VEGF) levels in CRC patients undergoing chemotherapy. The study group consisted of 18 CRC patients: 8 stage III colon cancer (CC) and 10 stage IV rectal cancer (RC) patients. EMPs, TAT and VEGF levels were assessed before chemotherapy and after the third course. Results were compared with 10 healthy subjects. EMP concentration was measured by flow cytometry, while TAT and VEGF concentrations were assayed employing ELISA. Compared to the control group, CC and RC patients had significantly higher levels of tissue factor (TF)-bearing and non-TF-bearing EMPs before and after three courses of chemotherapy. VEGF concentrations in CRC patients were higher than in the control groups and increased following chemotherapy. TAT levels were elevated in CRC patients before chemotherapy compared to healthy subjects and significantly increased after the third course of chemotherapy. No significant correlation was found either between EMP and TAT levels, or between EMP concentrations and VEGF levels in the study group. CRC patients have increased EMPs, and TAT as well as VEGF levels tend to increase during chemotherapy.

Indexed as

AdultAgedAntineoplastic Combined Chemotherapy ProtocolsAntithrombin IIICell-Derived MicroparticlesColorectal NeoplasmsFemaleHumansMaleMiddle AgedPeptide HydrolasesVascular Endothelial Growth Factor AAntithrombin IIIantithrombin III-protease complexPeptide HydrolasesVascular Endothelial Growth Factor AVEGFA protein, humanAngiogenesisBlood coagulationColorectal cancerEndothelium-derived microparticles

Identifiers

PMID32583332
PMCPMC7471181
OpenAlexW3037498808

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.